# Moderna

Type: Company (MRNA)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/moderna
Canonical HTML page: https://getfinancebrief.com/entity/moderna

## Timeline

- **2026-02-19**: Thursday Pre-Market — Key reports from Moderna, Newmont, Keurig Dr Pepper, Cheniere Energy, and Viatris.
- **2026-02-18**: FDA U-Turn — Moderna confirms the FDA has resolved the dispute and will now consider the vaccine for approval.
- **2026-02-18**: Wednesday Pre-Market — Key reports from Analog Devices, Kraft Heinz, Garmin, Wix.com, and Wingstop.
- **2026-02-15**: Public Dispute — Moderna and administration officials engage in a public disagreement over the regulatory path forward.
- **2026-02-10**: Initial Rejection — Reports emerge that the FDA vaccine chief overruled scientists to reject Moderna's flu shot filing.

## Recent coverage (6 stories)

### Axsome Revenue Doubles to $617M; 3 Biotechs Returned 230% vs. S&P 9% in H1
2026-07-07 06:57:49 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A trio of biotech stocks generated staggering H1 2026 returns, with Revolution Medicines leading at +230%. Axsome Therapeutics' revenue more than doubled to $617.1 million, underscoring a market rotation into catalyst-driven, high-growth healthcare plays amid macro uncertainty.
Full story: https://getfinancebrief.com/story/biotech-beats-sp500-financial-analysis

### Mid-Week Earnings Pulse: Tech, Consumer Staples, and Energy in Focus
2026-02-19 18:02:19 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A diverse slate of market leaders across semiconductors, consumer goods, and energy are set to report results, providing a critical pulse check on industrial demand and consumer spending. Key reports from Analog Devices, Moderna, and Kraft Heinz will highlight the divergent paths of the tech recovery and the healthcare sector's post-pandemic transition.
Full story: https://getfinancebrief.com/story/mid-week-earnings-preview-adi-mrna-khc-lng

### Midweek Market Pulse: Moderna and SanDisk Lead Sector-Specific Volatility
2026-02-19 01:48:21 · Sentiment: Neutral · Impact: 5/10 · Sources: 6

Investors are navigating a complex Wednesday session as major players in biotech, semiconductors, and leisure release pivotal updates. Market attention is centered on Moderna's pipeline diversification and SanDisk's recovery in the memory sector, signaling a shift toward fundamental-driven trading.
Full story: https://getfinancebrief.com/story/midweek-market-movers-moderna-sandisk-caesars

### FDA Reverses Stance on Moderna’s mRNA Flu Shot, Clearing Path for Review
2026-02-18 21:43:09 · Sentiment: Bullish · Impact: 7/10 · Sources: 3

The U.S. Food and Drug Administration has unexpectedly reversed its previous position, agreeing to review Moderna’s mRNA-based influenza vaccine candidate. This regulatory pivot marks a critical victory for Moderna as it seeks to diversify its portfolio beyond COVID-19 and challenge the traditional seasonal flu market.
Full story: https://getfinancebrief.com/story/fda-reversal-moderna-mrna-flu-shot-review

### YieldMax Declares Monthly Distributions Across Single-Stock Option ETFs
2026-02-18 19:58:48 · Sentiment: Neutral · Impact: 5/10 · Sources: 8

YieldMax has announced its latest round of monthly distributions for its suite of single-stock synthetic covered call ETFs, including those tracking MicroStrategy, Tesla, and Microsoft. The payouts reflect the varying volatility levels of the underlying assets, with MRNA and MSTR leading the distribution amounts.
Full story: https://getfinancebrief.com/story/yieldmax-etf-dividend-declarations-february-2026

### FDA Reverses Course on Moderna mRNA Flu Shot After Controversial Rejection
2026-02-18 18:57:55 · Sentiment: Bullish · Impact: 8/10 · Sources: 6

The U.S. Food and Drug Administration has agreed to review Moderna’s experimental mRNA flu vaccine, reversing a previous decision that sparked a public dispute. The initial rejection, which reportedly saw political appointees overrule career scientists, had briefly cast doubt on the regulatory path for the company's post-COVID pipeline.
Full story: https://getfinancebrief.com/story/fda-moderna-flu-shot-reversal

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.